Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | CPN1 | P15169 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | GRM8 | O00222 | 2/20 | 0.34 |
| ▸ | GRM6 | O15303 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2716357 | 0.83 | NSD2 (0.39) | NSD2GRM4CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL6293711 | 0.80 | NSD2 (0.41) | NSD2GRM4CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL17234576 | 0.78 | NSD2 (0.39) | F2CPN1CPB2NSD2GRM4 | |
| SCHEMBL23049641 | 0.77 | USP2 (0.43) | NSD2CYP1A2CYP2C19ALDH1A1TDP1 | |
| SCHEMBL19558975 | 0.73 | NSD2 (0.42) | NSD2GRM4CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL29006599 | 0.72 | GAA (0.34) | F2ALDH1A1KDM4E | |
| SCHEMBL4782515 | 0.72 | NSD2 (0.38) | NSD2GRM4CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL21777642 | 0.72 | NSD2 (0.38) | NSD2GRM4CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL1527385 | 0.71 | NSD2 (0.41) | NSD2GRM4CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL22958412 | 0.71 | F2 (0.48) | F2CPN1CPB2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139922-A1 | BACITRACIN-ALGINATE OLIGOMER CONJUGATES | ALGIPHARMA AS (NO) | 2023-05-04 | — | — | US | claimed |
| EP-3528830-B1 | POLYMYXIN-ALGINATE OLIGOMER CONJUGATES | ALGIPHARMA AS (NO) | 2022-10-05 | — | — | EP | claimed |
| US-20200138728-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2020-05-07 | — | — | US | claimed |
| US-20190328833-A1 | POLYMYXIN-ALGINATE OLIGOMER CONJUGATES | ALGIPHARMA AS (NO) | 2019-10-31 | — | — | US | claimed |
| EP-3528829-A1 | BACITRACIN-ALGINATE OLIGOMER CONJUGATES | Algipharma AS (NO) | 2019-08-28 | — | — | EP | claimed |
| EP-3528830-A1 | POLYMYXIN-ALGINATE OLIGOMER CONJUGATES | Algipharma AS (NO) | 2019-08-28 | — | — | EP | claimed |
| US-20180318231-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-11-08 | — | — | US | claimed |
| US-10022334-B2 | Cationic materials and formulations for drug delivery | The Brigham and Women's Hostpital, Inc. (US) | 2018-07-17 | — | — | US | claimed |
| WO-2018073449-A1 | POLYMYXIN-ALGINATE OLIGOMER CONJUGATES | ALGIPHARMA AS (NO) | 2018-04-26 | — | — | WO | claimed |
| WO-2018073448-A1 | BACITRACIN-ALGINATE OLIGOMER CONJUGATES | ALGIPHARMA AS (NO) | 2018-04-26 | — | — | WO | claimed |
| US-20160338970-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | claimed |
| WO-2015099985-A2 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-02 | — | — | WO | claimed |
| EP-4742904-A1 | CONJUGATES OF ANTIMICROBIAL AGENT AND A LINKER MOIETY SUITABLE FOR COVALENT ATTACHMENT TO MATERIALS AND SUBSTRATES | Amicoat AS (NO) | 2026-05-20 | — | — | EP | disclosed |
| EP-4646423-A1 | PEPTIDE SYNTHESIS METHOD INVOLVING STERICALLY HINDERED TRI-TERT-BUTYL-TRYPTOPHAN (TBT) RESIDUE | Amicoat AS (NO) | 2025-11-12 | — | — | EP | disclosed |
| US-20250332217-A1 | IMMUNE CHECKPOINT INHIBITOR COMBINATIONS | LYTIX BIOPHARMA AS (NO) | 2025-10-30 | — | — | US | disclosed |
| EP-4637799-A1 | MEDICAL PRODUCTS CONTAINING AN AQUEOUS FORMULATION OF A PEPTIDE | Lytix Biopharma AS (NO) | 2025-10-29 | — | — | EP | disclosed |
| US-20110172145-A1 | ANTIMICROBIAL COMPOUNDS | LYTIX BIOPHARMA AS (NO) | 2011-07-14 | — | — | US | disclosed |
| WO-2011051692-A1 | THERAPEUTIC PEPTIDES | LYTIX BIOPHARMA AS (NO) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010038040-A1 | TREATMENT OF BIOFILMS | LYTIX BIOPHARMA AS (NO) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038041-A1 | ANTIMICROBIAL COMPOUNDS | LYTIX BIOPHARMA AS (NO) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138728-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | SLC7A1, SLC43A1, AADAT | F2 1701/4885CPN1 705/4885CPB2 952/4885 |
| US-20180318231-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | SLC7A1, SLC43A1, AADAT | F2 1701/4885CPN1 705/4885CPB2 952/4885 |
| US-20230139922-A1 | BACITRACIN-ALGINATE OLIGOMER CONJUGATES | HDAC6, GNE, TBCA | F2 3788/4885CPN1 3027/4885CPB2 1866/4885 |
| US-20160338970-A1 | CATIONIC MATERIALS AND FORMULATIONS FOR DRUG DELIVERY | SLC7A1, SLC43A1, AADAT | F2 1523/4885CPN1 719/4885CPB2 940/4885 |
| US-10022334-B2 | Cationic materials and formulations for drug delivery | SLC7A1, SLC43A1, AADAT | F2 1523/4885CPN1 719/4885CPB2 940/4885 |
| US-20190328833-A1 | POLYMYXIN-ALGINATE OLIGOMER CONJUGATES | GNE, ALG1, ALG8 | F2 2880/4885CPN1 2571/4885CPB2 1666/4885 |
| US-20110172145-A1 | ANTIMICROBIAL COMPOUNDS | ZYX, DAO, SLC43A1 | F2 1110/4885CPN1 1694/4885CPB2 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.